Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
SEATTLE, Feb. 27, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017, at 3:20 p.m. Eastern time / 12:20 p.m. Pacific time in Boston.
A live audio webcast of the presentation will be available through the “Events & Presentations” page of the “News & Events” section of Cascadian Therapeutics’ website at cascadianrx.com. An archived edition of the session will be available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib (also known as ONT-380) is an oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.
Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected]
